In the randomised, Phase 3 CheckMate 214 trial, nivolumab (NIVO) + ipilimumab (IPI) has demonstrated durable survival and response benefit versus sunitinib (SUN) at all analyses,1-3 offering...

Alpelisib is an alpha-selective PI3K inhibitor. In combination with fulvestrant, it prolongs progression-free survival in postmenopausal women, and men, with HR+/HER2–, PIK3CA-mutated, advanced or...

PIK3CA mutations are present in approximately 40% of HR+ tumours.1 In clinical trials in women with HR+/HER2– advanced breast cancer, the frequency of PIK3CA mutations was 33–43%.2–4 SOLAR-1, a...

Advances in management have greatly improved outcomes for women with early breast cancer and drug treatment has replaced surgery as the primary treatment option for many patients.1 Advanced breast...

Breast cancer is among the most common cancers and a major cause of cancer-related death.1 Although the outlook for patients with early breast cancer is good, advanced breast cancer is still...

In the past decade, various targeted therapies have demonstrated improvement in outcomes for patients with advanced renal cell carcinoma (RCC).1 However, most patients on targeted therapy eventually...

The STEaM* Breast Cancer Symposium, a Novartis Australia initiative, took place in Sydney, Australia, on 11–12 October 2019. It was a highly anticipated multidisciplinary event that offered the...

Standard initial treatment for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer is endocrine therapy (ET).1 Current guidelines support the use of ET as monotherapy or...

The global incidence of melanoma has continued to rise dramatically over past decades.2-4 Prognosis varies with disease stage; while early-stage melanoma has an excellent long-term  prognosis with...

Endocrine therapy is standard-of-care in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, and is widely used to...